Castle Biosciences (CSTL) Other Accumulated Expenses (2018 - 2026)

Castle Biosciences has disclosed Other Accumulated Expenses across 9 years of filings, most recently posting $10.7 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $10.7 million, up 27.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.7 million (up 27.75% YoY), and the FY2025 annual result was $8.9 million, up 11.81% from the prior year.
• Other Accumulated Expenses came in at $10.7 million for Q1 2026 at Castle Biosciences, up from $8.9 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $10.7 million in Q1 2026 to a low of $5.1 million in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $7.4 million (2024), against an average of $7.4 million.
• Across the five-year window, Other Accumulated Expenses surged 223.84% in 2022 and declined 10.51% in 2023, its largest moves.
• Castle Biosciences' Other Accumulated Expenses stood at $5.3 million in 2022, then surged by 39.05% to $7.3 million in 2023, then climbed by 9.24% to $8.0 million in 2024, then advanced by 11.81% to $8.9 million in 2025, then rose by 19.63% to $10.7 million in 2026.
• The last three Other Accumulated Expenses figures came in at $10.7 million (Q1 2026), $8.9 million (Q4 2025), and $8.9 million (Q3 2025), per Business Quant data.